[89Zr]Zr-PSMA-617 PET/CT 在 [68Ga]Ga-PSMA-11 PET/CT 阴性前列腺癌生化复发中的检测效能
该回顾性研究纳入 23 例前列腺切除术后生化复发且 [68Ga]Ga-PSMA-11 PET/CT 阴性的男性,中位 PSA 0.54 ng/mL,评估 [89Zr]Zr-PSMA-617 PET/CT 的检测效能并比较 1 小时、24 小时和 48 小时扫描质量。18/23 例(78%)在 24 小时和 48 小时扫描(33 个病灶)或仅 48 小时扫描(3 个病灶)共发现 36 个可疑病灶;基于该检查接受放疗的 15 例患者 PSA 均下降。作者认为该检查似乎有效,48 小时扫描病灶与本底比值更优,值得前瞻性研究。
要点
- [68Ga]Ga-PSMA-11 PET/CT 阴性的生化复发患者中,18/23 例(78%)经 [89Zr]Zr-PSMA-617 PET/CT 发现可疑病灶。
- 24 小时与 48 小时扫描的放射性摄取无明确优劣,但 48 小时病灶与本底比值改善。
- 基于 [89Zr]Zr-PSMA-617 PET/CT 接受放疗的 15 例患者 PSA 值均下降。
核心结论
- 在低 PSA 的前列腺癌生化复发男性中,[89Zr]Zr-PSMA-617 PET/CT 似乎能有效发现 [68Ga]Ga-PSMA-11 PET/CT 未显示的前列腺恶性肿瘤。
- 48 小时扫描较 24 小时扫描检出率和病灶与本底比值更高,提示较晚时间点成像可能更可取。
- 作者认为值得对 [89Zr]Zr-PSMA-617 PET/CT 进行前瞻性研究。
研究设计与样本
- 回顾性分析 23 例前列腺切除术后生化复发男性,中位(最小-最大)PSA 0.54(0.11-2.50)ng/mL,40 ± 28 天前 [68Ga]Ga-PSMA-11 扫描阴性。
- 分析视觉所见及反映病灶 [89Zr]Zr-PSMA-617 摄取和病灶与本底比值的 PET 变量,并比较 1 小时、24 小时和 48 小时扫描质量。
- 主要终点为具有可疑病灶的患者百分比及可疑病灶分类。
主要发现
- 18/23 例患者(78%)在 24 小时和 48 小时扫描(33 个病灶)或仅 48 小时扫描(3 个病灶)共发现 36 个可疑病灶,每例 1-4 个。
- 仅 1 个病灶出现在 1 小时扫描。
- 病灶推测为局部复发 11 例,淋巴结或骨转移分别为 21 例或 4 例;1/1 个病灶经组织学证实为淋巴结转移。
- 基于 [89Zr]Zr-PSMA-617 PET/CT 接受放疗的全部 15 例患者,放疗后 PSA 值均下降。
- 24 小时与 48 小时扫描的 PET 变量比较提示两者在放射性示踪剂摄取方面无明确优劣,但 48 小时病灶与本底比值改善。
局限性
- 原文为回顾性分析。
- 作者在结论中提出值得对 [89Zr]Zr-PSMA-617 PET/CT 进行前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: In patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA) ligand radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h), which allow imaging ≥ 24 h post-injection, detect suspicious lesions that are missed when using tracers incorporating short-lived radionuclides. MATERIALS AND METHODS: To confirm [89Zr]Zr-PSMA-617 positron emission tomography/computed tomography (PET/CT) detection efficacy regarding such lesions, and compare quality of 1-h, 24-h, and 48-h [89Zr]Zr-PSMA-617 scans, we retrospectively analyzed visual findings and PET variables reflecting lesional [89Zr]Zr-PSMA-617 uptake and lesion-to-background ratio. The cohort comprised 23 men with BCR post-prostatectomy, median (minimum-maximum) prostate-specific antigen (PSA) 0.54 (0.11-2.50) ng/mL, and negative [68Ga]Ga-PSMA-11 scans 40 ± 28 d earlier. Primary endpoints were percentages of patients with, and classifications of, suspicious lesions. RESULTS: Altogether, 18/23 patients (78%) had 36 suspicious lesions (minimum-maximum per patient: 1-4) on both 24-h and 48-h scans (n = 33 lesions) or only 48-h scans (n = 3 lesions). Only one lesion appeared on a 1-h scan. Lesions putatively represented local recurrence in 11 cases, and nodal or bone metastasis in 21 or 4 cases, respectively; 1/1 lesion was histologically confirmed as a nodal metastasis. In all 15 patients given radiotherapy based on [89Zr]Zr-PSMA-617 PET/CT, PSA values decreased after this treatment. Comparison of PET variables in 24-h vs 48-h scans suggested no clear superiority of either regarding radiotracer uptake, but improved lesion-to-background ratio at 48 h. CONCLUSIONS: In men with BCR and low PSA, [89Zr]Zr-PSMA-617 PET/CT seems effective in finding prostate malignancy not seen on [68Ga]Ga-PSMA-11 PET/CT. The higher detection rates and lesion-to-background ratios of 48-h scans versus 24-h scans suggest that imaging at the later time may be preferable. Prospective study of [89Zr]Zr-PSMA-617 PET/CT is warranted.
引用
- Rosar F, Khreish F, Marlowe RJ, et al. Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 37148297. doi:10.1007/s00259-023-06241-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。